4.5 Article

Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine

Journal

VIROLOGY JOURNAL
Volume 5, Issue -, Pages -

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/1743-422X-5-39

Keywords

-

Categories

Funding

  1. NIAID NIH HHS [R56 AI015722, U54 AI057157, N01-AI-30049, N01-AI-15439, N01AI15439, I-U54-AI-057157, N01AI30049, 2R56AI015722-25] Funding Source: Medline

Ask authors/readers for more resources

Background: The vaccinia virus (VV) F2L gene encodes a functional deoxyuridine triphosphatase (dUTPase) that catalyzes the conversion of dUTP to dUMP and is thought to minimize the incorporation of deoxyuridine residues into the viral genome. Previous studies with with a complex, multigene deletion in this virus suggested that the gene was not required for viral replication, but the impact of deleting this gene alone has not been determined in vitro or in vivo. Although the crystal structure for this enzyme has been determined, its potential as a target for antiviral therapy is unclear. Results: The F2L gene was replaced with GFP in the WR strain of VV to assess its effect on viral replication. The resulting virus replicated well in cell culture and its replication kinetics were almost indistinguishable from those of the wt virus and attained similar titers. The virus also appeared to be as pathogenic as the WR strain suggesting that it also replicated well in mice. Cells infected with the dUTPase mutant would be predicted to affect pyrimidine deoxynucleotide pools and might be expected to exhibit altered susceptibility to pyrimidine analogs. The antiviral activity of cidofovir and four thymidine analogs were evaluated both in the mutant and the parent strain of this virus. The dUTPase knockout remained fully susceptible to cidofovir and idoxuridine, but was hypersensitive to the drug (N)-methanocarbathymidine, suggesting that pyrimidine metabolism was altered in cells infected with the mutant virus. The absence of dUTPase should reduce cellular dUMP pools and may result in a reduced conversion to dTMP by thymidylate synthetase or an increased reliance on the salvage of thymidine by the viral thymidine kinase. Conclusion: We confirmed that F2L was not required for replication in cell culture and determined that it does not play a significant role on virulence of the virus in intranasally infected mice. The recombinant virus is hypersensitive to (N)-methanocarbathymidine and may reflect metabolic differences in the mutant virus.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Medicinal

Dihydropyrimidinones and -thiones with improved activity against human polyomavirus family members

Alexandra Manos-Turvey, Hiba A. Al-Ashtal, Patrick G. Needham, Caroll B. Hartline, Mark N. Prichard, Peter Wipf, Jeffrey L. Brodsky

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)

Article Immunology

Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis

E. Randall Lanier, Scott Foster, Tom Brundage, Sunwen Chou, Mark N. Prichard, Steven Kleiboeker, Chad Wilson, Donella Colville, Herve Mommeja-Marin

JOURNAL OF INFECTIOUS DISEASES (2016)

Article Immunology

Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host

K. M. Mullane, C. Nuss, J. Ridgeway, M. N. Prichard, C. B. Hartline, J. Theusch, H. Mommeja-Marin, R. A. Larson

TRANSPLANT INFECTIOUS DISEASE (2016)

Article Virology

A Toolbox for Herpesvirus miRNA Research: Construction of a Complete Set of KSHV miRNA Deletion Mutants

Vaibhav Jain, Karlie Plaisance-Bonstaff, Rajnikumar Sangani, Curtis Lanier, Alexander Dolce, Jianhong Hu, Kevin Brulois, Irina Haecker, Peter Turner, Rolf Renne, Brian Krueger

VIRUSES-BASEL (2016)

Article Oncology

Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates

Kevin A. Cassady, David F. Bauer, Justin Roth, Melissa R. Chambers, Trent Shoeb, Jennifer Coleman, Mark Prichard, G. Yancey Gillespie, James M. Markert

MOLECULAR THERAPY-ONCOLYTICS (2017)

Article Pharmacology & Pharmacy

USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses

Karoly Toth, Jacqueline F. Spencer, Baoling Ying, Ann E. Tollefson, Caroll B. Hartline, Eric T. Richar, Jiajun Fan, Jinglei Lyu, Boris A. Kashemirov, Cheryl Harteg, Dawn Reyna, Elke Lipka, Mark N. Prichard, Charles E. McKenna, William S. M. Wold

ANTIVIRAL RESEARCH (2018)

Article Pharmacology & Pharmacy

Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis

Debra C. Quenelle, Alexander Birkmann, Thomas Goldner, Tamara Pfaff, Holger Zimmermann, Susanne Bonsmann, Deborah J. Collins, Terri L. Rice, Mark N. Prichard

ANTIVIRAL RESEARCH (2018)

Article Virology

Modified Cross-Linking, Ligation, and Sequencing of Hybrids (qCLASH) Identifies Kaposi's Sarcoma-Associated Herpesvirus MicroRNA Targets in Endothelial Cells

Lauren A. Gay, Sunantha Sethuraman, Merin Thomas, Peter C. Turner, Rolf Renne

JOURNAL OF VIROLOGY (2018)

Article Pharmacology & Pharmacy

New therapies for human cytomegalovirus infections

William J. Britt, Mark N. Prichard

ANTIVIRAL RESEARCH (2018)

Article Medicine, Research & Experimental

Xenotransplantation panel for the detection of infectious agents in pigs

Caroll B. Hartline, Ra'Shun L. Conner, Scott H. James, Jennifer Potter, Edward Gray, Jose Estrada, Mathew Tector, A. Joseph Tector, Mark N. Prichard

XENOTRANSPLANTATION (2018)

Article Pharmacology & Pharmacy

A standardized approach to the evaluation of antivirals against DNA viruses: Orthopox-, adeno-, and herpesviruses

Caroll B. Hartline, Kathy A. Keith, Jessica Eagar, Emma A. Harden, Terry L. Bowlin, Mark N. Prichard

ANTIVIRAL RESEARCH (2018)

Article Pharmacology & Pharmacy

A standardized approach to the evaluation of antivirals against DNA viruses: Polyomaviruses and lymphotropic herpesviruses

Kathy A. Keith, Caroll B. Hartline, Terry L. Bowlin, Mark N. Prichard

ANTIVIRAL RESEARCH (2018)

Article Biochemistry & Molecular Biology

Downregulation of the human peripheral myelin protein 22 gene by miR-29a in cellular models of Charcot-Marie-Tooth disease

Jacquelyn Serfecz, Hannah Bazick, Mohammed Omar Al Salihi, Peter Turner, Christopher Fields, Pedro Cruz, Rolf Renne, Lucia Notterpek

GENE THERAPY (2019)

Article Virology

Kaposi's Sarcoma-Associated Herpesvirus MicroRNA Mutants Modulate Cancer Hallmark Phenotypic Differences in Human Endothelial Cells

Lauren A. Gay, Daniel Stribling, Peter C. Turner, Rolf Renne

Summary: The study sheds light on the roles of individual miRNAs in KSHV-induced oncogenesis in endothelial cells. Different miRNAs have varying effects on cellular phenotypes, and new miRNA targets in specific pathways can be functionally validated through ribonomics data.

JOURNAL OF VIROLOGY (2021)

Article Pharmacology & Pharmacy

Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies

Donald F. Smee, Mark N. Prichard

ANTIVIRAL RESEARCH (2017)

No Data Available